An official website of the United States government
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Trial Status: complete
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin
(followed by brentuximab vedotin plus bendamustine in patient with suboptimal response)
is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible
patients are children, adolescents, and young adults relapsed or refractory to first
line.
Inclusion Criteria
Classic Hodgkin Lymphoma (cHL), relapsed or refractory
Minimal limitation on activities of daily living as measured by Karnofsky ≥ 50 for participants > 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age.
One prior anti-cancer therapy that did not work
Exclusion Criteria
Active, known, or suspected autoimmune disease or infection
Active cerebral/meningeal disease related to the underlying malignancy
More than one line of anti-cancer therapy or no treatment at all
Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant
Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors) Other protocol defined inclusion/exclusion criteria apply
Additional locations may be listed on ClinicalTrials.gov for NCT02927769.
